Adalimumab
An anti-TNF biologic you inject under your skin at home with a pen or syringe.
Also called: humira, hyrimoz, imraldi, idacio, yuflyma, ada, adalimumib, adalimuab
Related words anti-tnf biosimilar therapeutic drug monitoring
An anti-TNF biologic you inject under your skin at home with a pen or syringe.
Also called: humira, hyrimoz, imraldi, idacio, yuflyma, ada, adalimumib, adalimuab
Related words anti-tnf biosimilar therapeutic drug monitoring
A biosimilar is a version of a biologic medicine shown to have no meaningful differences in quality, safety or effectiveness from the original brand. For example, Remicade was the first infliximab and Remsima, Inflectra, Flixabi and Zessly are biosimilars; Humira was the first adalimumab and Amgevita, Hyrimoz, Imraldi, Idacio and Yuflyma are biosimilars. NHS England says switching between them is now accepted practice. A Cochrane review found infliximab and its CT-P13 biosimilar may work similarly.
Sources
Some people's bodies make antibodies against infliximab or adalimumab, which can stop the medicine working. Crohn's & Colitis UK says your team may check the level of medicine and antibodies in your blood. The 2025 BSG guideline says these tests can help decide whether to adjust treatment or switch to a different medicine, and NHS Lothian describes checking levels after starting and then at least yearly. Taking an immunomodulator alongside can lower the chance of antibodies.
Sources
Crohn's & Colitis UK explains that biologics are antibody medicines made by living cells in a lab. Each one targets a specific part of the immune system involved in inflammation: anti-TNFs (infliximab, adalimumab), the anti-integrin vedolizumab, and interleukin blockers (ustekinumab, risankizumab, mirikizumab, guselkumab). They are given by drip or by injection under the skin. Upadacitinib is a 'targeted' tablet, not a biologic.
Sources
There is no single best biologic for everyone. Trials comparing two drugs directly are still few: SEAVUE found ustekinumab and adalimumab worked about equally well in people new to biologics, and SEQUENCE found risankizumab was better than ustekinumab at healing the bowel in people for whom anti-TNF drugs had not worked. A 2026 Cochrane review comparing all the options says more head-to-head trials are needed.
Sources
NICE has approved infliximab and adalimumab (TA187), vedolizumab (TA352), ustekinumab (TA456), risankizumab (TA888), upadacitinib (TA905), mirikizumab (TA1080) and guselkumab (TA1095) for Crohn's, each under certain conditions. Most of the newer ones are for people whose disease has not responded to, or cannot have, an earlier treatment. Your IBD team decides with you which is suitable.
Sources
Describes a 23-year-old woman with Crohn's who developed pyoderma gangrenosum and improved on adalimumab, alongside a review of similar published cases. The authors stress early diagnosis and joint care between specialists.
Topics Beyond the gut Biologics and newer medicines
Jargon explained pyoderma gangrenosum adalimumab
A guide to adalimumab, an anti-TNF biologic you inject under your skin with a pen or syringe. It explains that Humira was the first brand and Amgevita, Hyrimoz, Idacio, Imraldi and Yuflyma are biosimilars, and that blood tests may check drug and antibody levels.
Topics Biologics and newer medicines Monitoring
Jargon explained anti-TNF biosimilar antibodies subcutaneous injection
NICE guidance on laboratory test kits that measure how much infliximab or adalimumab is in the blood and whether the body has made antibodies against the drug. The guidance was first published as diagnostics guidance 22 and has been moved into NICE's HealthTech programme without changing its content.
Topics Monitoring Biologics and newer medicines
Jargon explained therapeutic drug monitoring drug level anti-drug antibodies ELISA anti-TNF
NHS Lothian's IBD page on monitoring medicines. It explains that people on infliximab or adalimumab have their drug level checked some weeks after starting and then at least yearly, with anti-drug antibodies tested if the level is low.
Topics Monitoring Biologics and newer medicines
Jargon explained drug level anti-drug antibodies anti-TNF shared care
The NHS medicine guide to adalimumab, listing brands such as Amgevita, Humira, Imraldi and Yuflyma. It explains that it treats autoimmune conditions including Crohn's disease, is usually started by a specialist after other medicines have not worked, and needs regular blood tests.
Topics Biologics and newer medicines Medicines
Jargon explained biologic autoimmune condition biosimilar
The main trial behind adalimumab (Humira and its biosimilars) for keeping Crohn's under control. People who improved on adalimumab were much more likely to still be in remission at about a year if they kept taking it (36-41%) than if switched to placebo (12%). Taking it weekly worked no better than every other week.
Topics Biologics and newer medicines
Jargon explained maintenance remission CDAI placebo
Cochrane concluded that adalimumab works for keeping Crohn's in remission, including in people who had already tried another anti-TNF drug. Whether it helps after bowel surgery is still unclear.
Topics Biologics and newer medicines
Jargon explained anti-TNF maintenance quiescent
A Cochrane review with high-certainty evidence that adalimumab works better than placebo for bringing moderate to severe Crohn's into remission. Long-term safety needed more study.
NICE's appraisal approving infliximab and adalimumab on the NHS for adults with severe active Crohn's disease when standard treatments such as steroids or immunosuppressants have not worked or cannot be used. It applies to biosimilar versions too, and says treatment should be reviewed at least every 12 months to decide whether to continue.
Topics Biologics and newer medicines Medicines
Jargon explained anti-TNF biosimilar conventional therapy severe active Crohn's disease
NHS England's page on biosimilars: biological medicines shown to have no meaningful differences in quality, safety or effectiveness from the original brand. It explains why the NHS encourages their use, that switching between the original and a biosimilar is now accepted practice, and how savings are reinvested.
Topics Biologics and newer medicines Medicines
Jargon explained biosimilar originator medicine switching
One of the first 'head-to-head' trials comparing two biologics directly, in people who had never had a biologic. At one year, about 65% on ustekinumab and 61% on adalimumab were in remission, a difference too small to matter. Both worked well, so the choice between them can depend on other things such as preference and how the drug is given.
Topics Biologics and newer medicines Research
Jargon explained head-to-head trial biologic-naive confidence interval
A patient leaflet for people starting a biologic for IBD. It explains what biologics are, when they are used (often after steroids or azathioprine have not worked), and lists the biologics used at the hospital, their brands and how each is given.
Topics Biologics and newer medicines
Jargon explained biologic infusion biosimilar